Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepirovirsen - GSK

Next Previous
Drug Profile

Bepirovirsen - GSK

Alternative Names: 3228836; Bepirovirsen sodium; GSK'836; GSK-4388067; GSK-4388067A; GSK3228836; GSK3228836A; GSK3228836B; IONIS-HBVRx; ISIS 505358; ISIS-GSK3Rx; ISIS-HBVRx

Latest Information Update: 01 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer GSK
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Gene silencing; Hepatitis B surface antigen expression inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hepatitis B

Most Recent Events

  • 01 Jun 2026 GSK terminates phase-I/II trial in Hepatitis B (Combination therapy) in Thailand, Thailand, South Korea, Italy, France, Canada (SC) as a strategic decision (NCT05330455)
  • 28 May 2026 Bepirovirsen receives priority review designation for Hepatitis B in China
  • 28 May 2026 Updated adverse events and efficacy data from the phase-III B-Well-1 and B-Well-2 trials in Hepatitis B released by GSK

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top